E. David Crawford

12.7k total citations · 4 hit papers
133 papers, 9.1k citations indexed

About

E. David Crawford is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, E. David Crawford has authored 133 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pulmonary and Respiratory Medicine, 34 papers in Surgery and 26 papers in Oncology. Recurrent topics in E. David Crawford's work include Prostate Cancer Treatment and Research (75 papers), Prostate Cancer Diagnosis and Treatment (62 papers) and Bladder and Urothelial Cancer Treatments (27 papers). E. David Crawford is often cited by papers focused on Prostate Cancer Treatment and Research (75 papers), Prostate Cancer Diagnosis and Treatment (62 papers) and Bladder and Urothelial Cancer Treatments (27 papers). E. David Crawford collaborates with scholars based in United States, Canada and France. E. David Crawford's co-authors include Catherine M. Tangen, Ronald B. Natale, Michael F. Sarosdy, David P. Wood, Nicholas J. Vogelzang, V. O. Speights, Donald L. Trump, Ian M. Thompson, Derek Raghavan and H. Barton Grossman and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

E. David Crawford

131 papers receiving 8.8k citations

Hit Papers

Neoadjuvant Chemotherapy ... 1989 2026 2001 2013 2003 1989 2009 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
    2003 1.8k citations H. Barton Grossman, Ronald B. Natale et al. New England Journal of Medicine profile →
  2. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
    1989 1.2k citations E. David Crawford, Mario A. Eisenberger et al. New England Journal of Medicine profile →
  3. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial
    2009 826 citations Ian M. Thompson, Catherine M. Tangen et al. The Journal of Urology profile →
  4. Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer
    2006 664 citations Ian M. Thompson, Catherine M. Tangen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. David Crawford United States 38 5.1k 3.5k 1.6k 1.5k 992 133 9.1k
Nicolas Mottet France 36 6.8k 1.3× 1.5k 0.4× 698 0.4× 1.6k 1.1× 619 0.6× 147 8.6k
Gary D. Grossfeld United States 48 3.4k 0.7× 1.9k 0.5× 652 0.4× 1.4k 0.9× 311 0.3× 123 6.0k
Armen Aprikian Canada 48 4.2k 0.8× 3.0k 0.8× 946 0.6× 2.0k 1.4× 365 0.4× 279 8.7k
R. Jeffrey Karnes United States 59 8.5k 1.7× 2.8k 0.8× 800 0.5× 2.0k 1.4× 282 0.3× 428 12.4k
В. Б. Матвеев Russia 22 6.1k 1.2× 1.2k 0.3× 469 0.3× 1.5k 1.0× 402 0.4× 184 7.4k
Shin Egawa Japan 40 3.7k 0.7× 1.4k 0.4× 724 0.5× 1.3k 0.9× 260 0.3× 360 6.4k
Gabriel P. Haas United States 37 3.3k 0.6× 1.6k 0.5× 448 0.3× 1.3k 0.9× 349 0.4× 167 5.8k
Christer Busch Sweden 33 3.5k 0.7× 2.6k 0.7× 700 0.4× 1.3k 0.9× 131 0.1× 106 6.8k
Patrick J. Bastian Germany 58 4.6k 0.9× 4.7k 1.3× 2.3k 1.4× 1.4k 1.0× 153 0.2× 188 10.4k
J. Edson Pontes United States 43 3.5k 0.7× 1.9k 0.5× 444 0.3× 1.2k 0.8× 257 0.3× 155 6.0k

Countries citing papers authored by E. David Crawford

Since Specialization
Citations

This map shows the geographic impact of E. David Crawford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. David Crawford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. David Crawford more than expected).

Fields of papers citing papers by E. David Crawford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. David Crawford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. David Crawford. The network helps show where E. David Crawford may publish in the future.

Co-authorship network of co-authors of E. David Crawford

This figure shows the co-authorship network connecting the top 25 collaborators of E. David Crawford. A scholar is included among the top collaborators of E. David Crawford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. David Crawford. E. David Crawford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rove, Kyle O. & E. David Crawford. (2014). Traditional androgen ablation approaches to advanced prostate cancer: new insights.. PubMed. 21(2 Supp 1). 14–21. 20 indexed citations
3.
Hatoum, Hind T., et al.. (2013). Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 13(2). 251–259. 4 indexed citations
4.
Izmirlian, Grant, Robert L. Grubb, Amanda Black, et al.. (2009). PRE-BIOPSY PROSTATE CANCER NOMOGRAMS BASED UPON SERIAL PSA SCREENING DATA IN THE PLCO TRIAL WITH VERIFICATION BIAS CORRECTION. The Journal of Urology. 181(4). 609–609. 1 indexed citations
5.
6.
Swanson, Gregory P., Michael A. Hussey, Catherine M. Tangen, et al.. (2007). Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794. Journal of Clinical Oncology. 25(16). 2225–2229. 198 indexed citations
7.
Moinpour, Carol M., Katherine Hayden, Joseph M. Unger, et al.. (2007). Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy. Journal of Clinical Oncology. 26(1). 112–120. 109 indexed citations
8.
Herr, Harry W., James R. Faulkner, H. Barton Grossman, et al.. (2004). Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report. Journal of Clinical Oncology. 22(14). 2781–2789. 408 indexed citations
9.
Qi, Lin, Terry M. Nett, Gail S. Harrison, et al.. (2004). Binding and Cytotoxicity of Conjugated and Recombinant Fusion Proteins Targeted to the Gonadotropin-Releasing Hormone Receptor. Cancer Research. 64(6). 2090–2095. 33 indexed citations
10.
Grossman, H. Barton, Ronald B. Natale, Catherine M. Tangen, et al.. (2003). Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. New England Journal of Medicine. 349(9). 859–866. 1834 indexed citations breakdown →
11.
Campbell, Timothy, John C. Blasko, E. David Crawford, et al.. (2001). Clinical staging of prostate cancer: Reproducibility and clarification of issues. International Journal of Cancer. 96(3). 198–209. 19 indexed citations
12.
Porter, Christopher R., Colin O’Donnell, E. David Crawford, et al.. (2001). Artificial Neural Network Model To Predict Biochemical Failure After Radical Prostatectomy. PubMed. 5(4). 159–162. 18 indexed citations
13.
Gelmann, Edward P., David Chia, Paul F. Pinsky, et al.. (2001). Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology. 58(4). 561–566. 22 indexed citations
14.
White, Ralph W. deVere, Arline D. Deitch, Siamak Daneshmand, et al.. (2000). The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer. European Urology. 37(5). 595–600. 13 indexed citations
15.
Hirano, Daisaku, Priya N. Werahera, E. David Crawford, et al.. (1998). MORPHOLOGICAL ANALYSIS AND CLASSIFICATION OF LATENT PROSTATE CANCER USING A 3-DIMENSIONAL COMPUTER ALGORITHM: ANALYSIS OF TUMOR VOLUME, GRADE, TUMOR DOUBLING TIME AND LIFE EXPECTANCY. The Journal of Urology. 159(4). 1265–1269. 16 indexed citations
16.
Williamson, Stephen K., Michael Wolf, Mario A. Eisenberger, et al.. (1996). Phase II Evaluation of Ifosfamide/Mesna in Metastatic Prostate Cancer. American Journal of Clinical Oncology. 19(4). 368–370. 6 indexed citations
17.
18.
Pummer, Karl, et al.. (1994). Hormonal pretreatment does not affect the final pathologic stage in locally advanced prostate cancer. Urology. 44(6). 38–42. 12 indexed citations
19.
Crawford, E. David, et al.. (1992). Treatment of stages B3 and C seminoma with chemotherapy followed by irradiation therapy. Urology. 39(5). 457–460. 3 indexed citations
20.
Crawford, E. David. (1989). Combined androgen blockade. Urology. 34(4). 22–26. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Mottet Breakdown of academic impact, for papers by Gary D. Grossfeld Breakdown of academic impact, for papers by Armen Aprikian Breakdown of academic impact, for papers by R. Jeffrey Karnes Breakdown of academic impact, for papers by В. Б. Матвеев Breakdown of academic impact, for papers by Shin Egawa Breakdown of academic impact, for papers by Gabriel P. Haas Breakdown of academic impact, for papers by Christer Busch Breakdown of academic impact, for papers by Patrick J. Bastian Breakdown of academic impact, for papers by J. Edson Pontes
Rankless by CCL
2026